CLINICAL EFFICACY OF MODIFIED GOOSE-FAT-BASED TOPICAL OINTMENTS IN CHRONIC ALLERGIC DERMATITIS: A COMPARATIVE CLINICAL ANALYSIS

Authors

Keywords:

chronic allergic dermatitis; eczema; goose fat; Aloe vera; betamethasone; topical formulation; clinical response; skin-barrier function; pruritus; comparative analysis.

Abstract

Chronic allergic dermatitis encompasses persistent or recurrent eczematous conditions with pruritus, erythema, excoriation and epidermal barrier dysfunction. This study examines clinical changes reported during the use of two modified goose-fat-based topical formulations compared with conventional betamethasone treatment. The source manuscript describes 268 patients treated between 2018 and 2024 at clinical facilities of Bukhara State Medical Institute and classified into three treatment groups: goose fat, aloe extract and betamethasone; goose fat and aloe extract; or topical betamethasone. Lesion counts were documented at baseline, one month and three months, alongside descriptions of laboratory, immunological, morphological and formulation assessments. Across all three groups, reported counts of papules, vesicles and excoriations decreased during follow-up. In the combined-formulation group, papular findings declined from 71 at baseline to 16 at three months, vesicles from 51 to 5, and excoriations from 60 to 10. Corresponding baseline-to-three-month papule counts were 78 to 3 in the goose-fat–aloe group and 81 to 11 in the betamethasone group. However, inconsistencies in stated denominators, incomplete allocation and safety details, and conflicting scratch-mark percentages limit formal between-group comparison. This revised analysis places the results in the context of contemporary evidence on skin-barrier repair and topical anti-inflammatory therapy. The observed within-group improvements are encouraging, but the independent benefits and safety of the experimental formulations require confirmation in rigorously reported controlled studies.

References

1.Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2024;190(1):55–61. doi:10.1093/bjd/ljad339.

2.Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi:10.1016/S0140-6736(20)31286-1.

3.Elias PM, Wakefield JS. Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):781–791.e1. doi:10.1016/j.jaci.2014.05.048.

4.Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1–e20. doi:10.1016/j.jaad.2022.12.029.

5.Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 AAAAI/ACAAI Joint Task Force recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274–312. doi:10.1016/j.anai.2023.11.009.

6.van Halewijn KF, Lahnstein T, Bohnen AM, et al. Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines. Eur J Dermatol. 2022;32(1):113–123. doi:10.1684/ejd.2022.4197.

7.van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen APM, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:CD012119. doi:10.1002/14651858.CD012119.pub2.

8.Spada F, Harrison IP, Barnes TM, et al. A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: a randomized trial. Dermatol Ther. 2021;34(4):e14970. doi:10.1111/dth.14970.

9.Elias PM. Optimizing emollient therapy for skin barrier repair in atopic dermatitis. Ann Allergy Asthma Immunol. 2022;128(5):505–511. doi:10.1016/j.anai.2022.01.012.

10.Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: a Cochrane systematic review and network meta-analysis. Clin Exp Allergy. 2024;54(12):960–972. doi:10.1111/cea.14556.

11.Harvey J, Lax SJ, Lowe A, et al. The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health Dis. 2023;3(5):e268. doi:10.1002/ski2.268.

12.Chan CX, Zug KA. Diagnosis and management of dermatitis, including atopic, contact, and hand eczemas. Med Clin North Am. 2021;105(4):611–626. doi:10.1016/j.mcna.2021.04.003.

13.Dickel H, Bauer A, Brehler R, et al. German S1 guideline: contact dermatitis. J Dtsch Dermatol Ges. 2022;20(5):712–734. doi:10.1111/ddg.14734.

14.Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357–378. doi:10.1111/cod.14035.

15.Hekmatpou D, Mehrabi F, Rahzani K, Aminiyan A. The effect of Aloe vera clinical trials on prevention and healing of skin wound: a systematic review. Iran J Med Sci. 2019;44(1):1–9. PMID:30666070.

16.Karimova FR. Evaluation of the efficacy of an ointment containing goose fat, extract aloe, and betamethasone in preclinical studies for the treatment of allergic dermatitis. Central Asian Journal of Medicine. 2025;(5):19–23. https://journals.tma.uz/index.php/cajm/article/view/1425.

17.Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11–18. doi:10.1034/j.1600-0625.2001.100102.x.

18.Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x.

Published

2026-11-06